Company intelligence / Profile preview

Complement Pharma

Amsterdam, Noord-Holland, Netherlandscomplementpharma.com ↗

Ownership: Private
Development stage: Preclinical

Overview

No detailed clinical results available. The company was acquired by Graviton Bioscience in December 2022, suggesting it had promising assets or technology in complement-targeted therapeutics but no public late-stage data.

Therapeutic areas: Immunology
Modalities: Likely biologics or small molecules targeting the complement system (inferred from industry context)
Industry: Biotech

Drug pipeline

1 asset

CP010

Unknown

Beyond the preview

Go deeper on Complement Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Complement Pharma.

Explore the full profile